With more than 30 years of scientific research cooperation experience, Shanghai Mental Health Center and Shanghai Institute of Materia Medica have forged a sincere and deep bond. A multi-level pharmaceutical collaboration has been established during the clinical research of the innovative drug GV-971 for the treatment of Alzheimer's disease and the innovative drug TPN-672 for the treatment of schizophrenia. In January 2020, the two parties formally signed a strategic cooperation agreement. In July 2020, the innovative clinical research base and union laboratory of psychiatric drug fusion and integration were unveiled.

Guided by clinical needs, the union laboratory aims to conduct research on pathogenesis of mental diseases that seriously endanger people's lives and health, discovery and confirmation of new drug targets, mechanism of drug action, and preclinical and clinical research of innovation drugs. With both efforts, we strive to make breakthroughs so as to speed up the clinical research and translational application of innovative drugs in the field of mental health, and gain progress through an integrated innovative cooperation model; and finally promotes Shanghai City Mental Health Center to become a research-oriented special hospital with international influence.